We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

200 hedge funds and large institutions have $2.04B invested in Sage Therapeutics in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 60 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

259% more call options, than puts

Call options by funds: $23.4M | Put options by funds: $6.52M

24% more capital invested

Capital invested by funds: $1.65B → $2.04B (+$396M)

13% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 60

1.55% more ownership

Funds ownership: 86.31% → 87.86% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 209 → 200 (-9)

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

Holders
200
Holders Change
-9
Holders Change %
-4.31%
% of All Funds
3.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
68
Reduced
60
Closed
30
Calls
$23.4M
Puts
$6.52M
Net Calls
+$16.9M
Net Calls Change
+$10.2M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$26.9M
2
BlackRock
BlackRock
New York
+$22.4M
3
Fisher Asset Management
Fisher Asset Management
Washington
+$17.2M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$16.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.2M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$23.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$17.7M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$11.7M
4
Morgan Stanley
Morgan Stanley
New York
-$8.99M
5
DTC
Deep Track Capital
Connecticut
-$5.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
201
Natixis
France
– -$1.14M -35,200 Closed
Walleye Capital
202
Walleye Capital
New York
– -$1.28M -33,199 Closed
DA
203
Duality Advisers
Florida
– -$624K -19,334 Closed
CANY
204
Caxton Associates (New York)
New York
– -$595K -18,426 Closed
SIM
205
SummerHaven Investment Management
Connecticut
– -$586K -18,130 Closed
Simplex Trading
206
Simplex Trading
Illinois
– -$669K -17,320 Closed
FRM
207
Fox Run Management
Connecticut
– -$559K -17,298 Closed
BF
208
BOK Financial
Oklahoma
– -$547K -16,933 Closed
DTL
209
Dynamic Technology Lab
Singapore
– -$539K -16,680 Closed
SM
210
SG3 Management
Puerto Rico
– -$517K -16,000 Closed
TC
211
TwinBeech Capital
New York
– -$503K -15,562 Closed
ACM
212
Altium Capital Management
New York
– -$485K -15,000 Closed
AIM
213
Aigen Investment Management
New York
– -$405K -12,524 Closed
PI
214
Putnam Investments
Massachusetts
– -$338K -10,488 Closed
PHK
215
Point72 Hong Kong
Hong Kong
– -$321K -9,927 Closed
PI
216
PEAK6 Investments
Illinois
– -$348K -9,000 Closed
Federated Hermes
217
Federated Hermes
Pennsylvania
– -$245K -7,584 Closed
JF
218
Jump Financial
Illinois
– -$218K -6,745 Closed
CM
219
Caption Management
Oklahoma
– -$141K -4,362 Closed
GCM
220
Gladius Capital Management
Illinois
– -$18K -539 Closed
CAPTRUST Financial Advisors
221
CAPTRUST Financial Advisors
North Carolina
– -$13K -402 Closed
PFGIA
222
Patriot Financial Group Insurance Agency
Massachusetts
– -$4K -139 Closed
DI
223
Disciplined Investments
Oklahoma
– +$116 +3 +150%
SIC
224
SJS Investment Consulting
Ohio
– +$348 +9 New
5 6 7 8
9

SAGE Hedge Fund Activity: Q3 2022 in Review

200 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2022, worth a combined $2.04B — up 24% from $1.65B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of SAGE and 23 opened new positions — a net loss of 7 holders — while 60 trimmed existing stakes and 68 added.

The largest buyer was Janus Henderson Group, adding an estimated $26.9M. The largest seller was Marshall Wace, cutting an estimated $23.7M.

  • 200 institutional investors held Sage Therapeutics (SAGE) as of Q3 2022, down from 209 in Q2 2022.
  • Funds reported $2.04B of Sage Therapeutics stock for Q3 2022, up 24% quarter-over-quarter.
  • 23 funds opened new Sage Therapeutics positions in Q3 2022 and 30 closed out, a net change of -7 holders.
  • The largest Sage Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $26.9M added.
  • The largest Sage Therapeutics seller in Q3 2022 was Marshall Wace, an estimated $23.7M sold.

Based on aggregated 13F filings for Q3 2022.